TTKHLTCARE.NS
TTK Healthcare Limited [TTKHLTCARE.NS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TTKHLTCARE.NS Stock Summary
Top 10 Correlated ETFs
TTKHLTCARE.NS
Top 10 Correlated Stocks
TTKHLTCARE.NS
In the News
TTKHLTCARE.NS Financial details
Company Rating
Buy
Market Cap
22.73B
Income
615.13M
Revenue
7.52B
Book val./share
-
Cash/share
-
Dividend
10
Dividend %
0.72%
Employees
1.29K
Optionable
No
Shortable
Yes
Earnings
21 May 2024
P/E
32.58
Forward P/E
-
PEG
6.8
P/S
2.63
P/B
2.03
P/C
-
P/FCF
-
Quick Ratio
4.74
Current Ratio
5.26
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
43.54
EPS next Y
-
EPS next Q
-
EPS this Y
1438.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
92.23%
Revenue last 5Y
2.98%
Revenue Q/Q
-1.03%
EPS Q/Q
-19.42%
-
-
-
-
SMA20
5.33%
SMA50
9.59%
SMA100
22.79%
Inst Own
-
Inst Trans
-
ROA
5%
ROE
13%
ROC
0.08%
Gross Margin
55%
Oper. Margin
10%
Profit Margin
8%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1101.2-1744.0
52W High
-12.36%
52W Low
+38.82%
RSI
49
Rel Volume
0.2
Avg Volume
22.54K
Volume
4.44K
Perf Week
-7.26%
Perf Month
2.39%
Perf Quarter
24.99%
Perf Half Y
28.52%
-
-
-
-
Beta
0.631
-
-
Volatility
48.67%, 58.96%
Prev Close
-0.55%
Price
1528.45
Change
-1.14%
TTKHLTCARE.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-03-31
| Metric | History | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 443.15 | 456.23 | 448.28 | 421.85 | 513.17 | |
| Net income per share | 17.25 | 8.72 | 32.87 | 29.43 | 452.73 | |
| Operating cash flow per share | 12.25 | 14.04 | 68.24 | 31.84 | -18.45 | |
| Free cash flow per share | 9.19 | 5.38 | 67.01 | 27.25 | -26.73 | |
| Cash per share | 88.42 | 93.04 | 160.75 | 193.2 | 616.66 | |
| Book value per share | 177.94 | 176.22 | 208.53 | 233.28 | 674.72 | |
| Tangible book value per share | 177.7 | 176.05 | 208.42 | 233.22 | 674.7 | |
| Share holders equity per share | 177.94 | 176.22 | 208.53 | 233.28 | 674.72 | |
| Interest debt per share | 22.51 | 23.34 | 15.04 | 18.01 | 23.05 | |
| Market cap | 9.76B | 4.49B | 6.99B | 11.73B | 14.67B | |
| Enterprise value | 9.94B | 4.72B | 7.09B | 11.8B | 14.85B | |
| P/E ratio | 40.06 | 36.47 | 15.05 | 28.21 | 2.29 | |
| Price to sales ratio | 1.56 | 0.7 | 1.1 | 1.97 | 2.02 | |
| POCF ratio | 56.42 | 22.65 | 7.25 | 26.07 | -56.25 | |
| PFCF ratio | 75.24 | 59.09 | 7.38 | 30.47 | -38.83 | |
| P/B Ratio | 3.88 | 1.8 | 2.37 | 3.56 | 1.54 | |
| PTB ratio | 3.88 | 1.8 | 2.37 | 3.56 | 1.54 | |
| EV to sales | 1.59 | 0.73 | 1.12 | 1.98 | 2.05 | |
| Enterprise value over EBITDA | 17.01 | 12.39 | 15.68 | 30.28 | 18.61 | |
| EV to operating cash flow | 57.42 | 23.77 | 7.35 | 26.23 | -56.94 | |
| EV to free cash flow | 76.58 | 62.03 | 7.48 | 30.66 | -39.3 | |
| Earnings yield | 0.02 | 0.03 | 0.07 | 0.04 | 0.44 | |
| Free cash flow yield | 0.01 | 0.02 | 0.14 | 0.03 | -0.03 | |
| Debt to equity | 0.11 | 0.12 | 0.06 | 0.07 | 0.03 | |
| Debt to assets | 0.07 | 0.07 | 0.04 | 0.04 | 0.02 | |
| Net debt to EBITDA | 0.3 | 0.59 | 0.21 | 0.19 | 0.23 | |
| Current ratio | 1.73 | 1.74 | 1.99 | 2.03 | 5.06 | |
| Interest coverage | 11.01 | 4.61 | 3.06 | 2.87 | 3.57 | |
| Income quality | 0.44 | 1.02 | 2.6 | 0.78 | -0.03 | |
| Dividend Yield | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.35 | 0.69 | 0.09 | 0.2 | 0.02 | |
| Sales general and administrative to revenue | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | |
| Research and developement to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.25 | -0.62 | -0.02 | -0.14 | 0.45 | |
| Capex to revenue | -0.01 | -0.02 | 0 | -0.01 | -0.02 | |
| Capex to depreciation | -0.3 | -0.85 | -0.13 | -0.49 | -0.91 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 262.8 | 185.92 | 392.69 | 393.05 | 2.62K | |
| ROIC | 0.08 | 0.03 | 0.03 | 0.02 | 0.01 | |
| Return on tangible assets | 0.06 | 0.03 | 0.09 | 0.07 | 0.55 | |
| Graham Net | 35.81 | 33.19 | 79.78 | 104.69 | 542.07 | |
| Working capital | 1.15B | 1.26B | 1.86B | 2.28B | 8.55B | |
| Tangible asset value | 2.51B | 2.49B | 2.94B | 3.3B | 9.53B | |
| Net current asset value | 1.07B | 1.15B | 1.75B | 2.2B | 8.49B | |
| Invested capital | 0.11 | 0.12 | 0.06 | 0.07 | 0.03 | |
| Average receivables | 415.87M | 828.01M | 745.83M | 762.94M | 889.75M | |
| Average payables | 795.24M | 796.14M | 920.58M | 1.01B | 1.14B | |
| Average inventory | 541.02M | 634.77M | 709.74M | 746.14M | 817.2M | |
| Days sales outstanding | 48.48 | 46.67 | 38.46 | 52.57 | 46.36 | |
| Days payables outstanding | 100.46 | 120.67 | 140.26 | 131.57 | 130.62 | |
| Days of inventory on hand | 76.41 | 99.93 | 101.03 | 100.37 | 88.7 | |
| Receivables turnover | 7.53 | 7.82 | 9.49 | 6.94 | 7.87 | |
| Payables turnover | 3.63 | 3.02 | 2.6 | 2.77 | 2.79 | |
| Inventory turnover | 4.78 | 3.65 | 3.61 | 3.64 | 4.11 | |
| ROE | 0.1 | 0.05 | 0.16 | 0.13 | 0.67 | |
| Capex per share | -3.06 | -8.66 | -1.23 | -4.6 | -8.28 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q3
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 129.2 | 127.48 | 143.04 | 131.47 | 130.11 | |
| Net income per share | 8.49 | 11.99 | 11.09 | 11.33 | 9.13 | |
| Operating cash flow per share | 4.54 | 4.36 | 4.47 | 4.64 | 4.68 | |
| Free cash flow per share | 4.54 | 4.36 | 4.47 | 4.64 | 4.68 | |
| Cash per share | 0 | 616.65 | 0 | 620.86 | 0 | |
| Book value per share | 0 | 674.71 | 0 | 688.14 | 0 | |
| Tangible book value per share | 0 | 674.68 | 0 | 688.12 | 0 | |
| Share holders equity per share | 0 | 674.71 | 0 | 688.14 | 0 | |
| Interest debt per share | 0.55 | 20.02 | 0.61 | 18.13 | 0.17 | |
| Market cap | 14.22B | 14.67B | 17.86B | 16.41B | 19.61B | |
| Enterprise value | 14.22B | 14.85B | 17.86B | 16.58B | 19.61B | |
| P/E ratio | 29.63 | 21.64 | 28.49 | 25.63 | 38.02 | |
| Price to sales ratio | 7.79 | 8.14 | 8.84 | 8.83 | 10.67 | |
| POCF ratio | 221.55 | 238.17 | 282.94 | 250.28 | 296.64 | |
| PFCF ratio | 221.55 | 238.17 | 282.94 | 250.28 | 296.64 | |
| P/B Ratio | 0 | 1.54 | 0 | 1.69 | 0 | |
| PTB ratio | 0 | 1.54 | 0 | 1.69 | 0 | |
| EV to sales | 7.79 | 8.24 | 8.84 | 8.93 | 10.67 | |
| Enterprise value over EBITDA | 70.33 | 48.22 | 72.43 | 64.86 | 92.32 | |
| EV to operating cash flow | 221.55 | 241.1 | 282.94 | 252.91 | 296.64 | |
| EV to free cash flow | 221.55 | 241.1 | 282.94 | 252.91 | 296.64 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0 | 0.03 | 0 | 0.03 | 0 | |
| Debt to assets | 0 | 0.02 | 0 | 0.02 | 0 | |
| Net debt to EBITDA | 0 | 0.58 | 0 | 0.67 | 0 | |
| Current ratio | 0 | 5.06 | 0 | 5.26 | 0 | |
| Interest coverage | 21.8 | 29.06 | 8.01 | 30.48 | 76.38 | |
| Income quality | 0.54 | 0.36 | 0.4 | 0.41 | 0.51 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | -0.28 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0.01 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0 | 426.64 | 0 | 418.79 | 0 | |
| ROIC | 0 | 0.02 | 0 | 0.02 | 0 | |
| Return on tangible assets | 0 | 0.01 | 0 | 0.01 | 0 | |
| Graham Net | 0 | 542.06 | 0 | 553 | 0 | |
| Working capital | 9.52B | 8.55B | 8.47B | 8.72B | 0 | |
| Tangible asset value | 0 | 9.53B | 0 | 9.72B | 0 | |
| Net current asset value | 9.52B | 8.49B | 8.47B | 8.67B | 0 | |
| Invested capital | 0 | 0.03 | 0 | 0.03 | 0 | |
| Average receivables | 384.89M | 460.5M | 460.5M | 461.77M | 461.77M | |
| Average payables | 615.32M | 622.3M | 622.3M | 604.15M | 604.15M | |
| Average inventory | 379.92M | 422.57M | 422.57M | 447.61M | 447.61M | |
| Days sales outstanding | 0 | 46.01 | 0 | 44.74 | 0 | |
| Days payables outstanding | 0 | 129.55 | 0 | 130.04 | 0 | |
| Days of inventory on hand | 0 | 87.97 | 0 | 96.34 | 0 | |
| Receivables turnover | 0 | 1.96 | 0 | 2.01 | 0 | |
| Payables turnover | 0 | 0.69 | 0 | 0.69 | 0 | |
| Inventory turnover | 0 | 1.02 | 0 | 0.93 | 0 | |
| ROE | 0 | 0.02 | 0 | 0.02 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
TTKHLTCARE.NS Frequently Asked Questions
What is TTK Healthcare Limited stock symbol ?
TTK Healthcare Limited is a IN stock and trading under the symbol TTKHLTCARE.NS
What is TTK Healthcare Limited stock quote today ?
TTK Healthcare Limited stock price is $1528.45 today.
Is TTK Healthcare Limited stock public?
Yes, TTK Healthcare Limited is a publicly traded company.
Something similar
Company Profile
- Volume Average 22.54K
- Market Capitalization 22.73B
- Employee 1.29K
- CEO Mr. T. T. Raghunathan B.Com.
- Headquarters Chennai,IN
- IPO Date 2010-01-08
-
Website
https://www.ttkhealthcare.com 
TTK Healthcare Limited engages in the animal welfare and human pharma product, consumer product, medical device, protective device, and food businesses in India and internationally. Its Animal Welfare segment deals in various therapeutic formulations and feed supplements for veterinary use. The company's Consumer Products segment is involved in the marketing and distribution of Woodward's Gripewater, EVA range of cosmetics, Good Home range of scrubbers, air fresheners, etc. its Medical Devices segment manufactures and distributes artificial heart valves; and develops orthopedic implants and instruments. The company's Protective Devices segment manufactures and markets male contraceptives and other allied products. Its Foods segment engages in the manufacturing and marketing of food products, including potato and cereal based pellets. The company's Others segment prints and publishes maps and atlases. Its Human Pharma segment deals in herbal and allopathic formulations for human use. The company was incorporated in 1958 and is headquartered in Chennai, India. TTK Healthcare Limited is a subsidiary of TT Krishnamachari & Co., Ltd.
